On March 24, Guiyang Xintian Pharmaceutical Co.Ltd(002873) ( Guiyang Xintian Pharmaceutical Co.Ltd(002873) ) released the annual report for 2021. The company’s revenue was 970 million yuan, an increase of 29.15% year-on-year; The net profit attributable to shareholders of listed companies was 101 million yuan, with a year-on-year increase of 35.76%; The deducted non net profit attributable to shareholders of listed companies was 94 million yuan, with a year-on-year increase of 32.21%; Complete the performance growth target of the first year of the “three-year doubling plan”.
Guiyang Xintian Pharmaceutical Co.Ltd(002873) said that during the reporting period, while doing a good job in various operations and management, the company continued to optimize the sales product structure, and the gross profit margin of main products increased year-on-year. Among them, the revenue of gynecological products was 686 million yuan, accounting for 70.78% of the total revenue, with a year-on-year increase of 31.83%; The revenue of urinary system was 202 million yuan, with a year-on-year increase of 22.76%.
As a modern traditional Chinese medicine pharmaceutical enterprise integrating new drug research and development, drug production and sales, Guiyang Xintian Pharmaceutical Co.Ltd(002873) 2005 started the information construction in the field of logistics, and actively promoted the cost reduction and efficiency increase of traditional Chinese medicine logistics. In 2021, the company further applied modern new technology to the production and operation of the enterprise, and various engineering construction projects such as Guiyang R & D center and capacity supply guarantee center were successively completed and put into operation. The company improves the automation and informatization level of production by promoting green manufacturing and intelligent manufacturing; Improve the production efficiency of each process by reducing unit energy consumption. In 2021, the gross profit margin of the company’s main business was 79.28%, an increase of 1.27% compared with 2020.
According to the financial report data, during the reporting period, the company’s sales expense rate and management expense rate accounted for 48.65% and 13.85% respectively, which decreased by 0.07% and 0.60% respectively compared with 2020. The management ability was further improved, and the costs and expenses were further controlled. Among them, the costs and expenses include the estimated amortization of equity incentive of 8.88 million yuan this year. With a series of optimization measures such as refined management, efficiency improvement and cost control, the operation efficiency will be further improved, and the profitability is expected to continue to grow in the future.
In the first half of 2021, the company set the performance target of doubling the operating revenue in three years and launched the first equity incentive plan after listing. A total of 3.17 million restricted incentive shares were granted to 60 management and technical backbone employees, focusing on the company’s marketing and R & D system.
The announcement shows that the performance goal of the three-year revenue doubling plan is based on the operating revenue of Guiyang Xintian Pharmaceutical Co.Ltd(002873) 2020, and requires the company to maintain an average annual growth of 27% in the next three years. During the reporting period, Guiyang Xintian Pharmaceutical Co.Ltd(002873) revenue increased by 29.15% year-on-year, successfully taking the first step of the three-year doubling plan, which verified the effective implementation and actual implementation of the three-year doubling goal by the company’s management in stages.
Guiyang Xintian Pharmaceutical Co.Ltd(002873) said that the implementation of the equity incentive plan has fully mobilized the work enthusiasm of the company’s core employees, centered on market promotion and product research and development, and provided strong power support and measure guarantee for the doubling of three-year performance. In terms of marketing, the company continued to optimize the personnel structure of the marketing team, adhered to “stimulating the OTC channel market with clinical efficacy”, and continuously improved the product coverage of chain pharmacies.
